The aim of this trial is to optimize management of ALK+ NSCLC by analyzing the efficacy of brigatinib and other ALK TKI in conjunction with deep clinical and molecular patient phenotyping across two treatment lines. This evidence concerns the gene ALK and non-small cell lung carcinoma.